GUCY1B1

Summary

GUCY1B1 (guanylate cyclase 1 soluble subunit beta 1, HGNC:4687) is a protein-coding gene on chromosome 4q32.1, encoding Guanylate cyclase soluble subunit beta-1 (Q02153). Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP.

This gene encodes the beta subunit of the soluble guanylate cyclase (sGC), which catalyzes the conversion of GTP (guanosine triphosphate) to cGMP (cyclic guanosine monophosphate). The encoded protein contains an HNOX domain, which serves as a receptor for ligands such as nitric oxide, oxygen and nitrovasodilator drugs. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 2983 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 55 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000857

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4687
Approved symbol	GUCY1B1
Name	guanylate cyclase 1 soluble subunit beta 1
Location	4q32.1
Locus type	gene with protein product
Status	Approved
Aliases	GC-SB3, GC-S-beta-1
Ensembl gene	ENSG00000061918
Ensembl biotype	protein_coding
OMIM	139397
Entrez	2983

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 18 protein_coding

ENST00000264424, ENST00000502959, ENST00000503520, ENST00000505154, ENST00000505764, ENST00000507146, ENST00000513437, ENST00000652626, ENST00000879916, ENST00000879917, ENST00000879918, ENST00000879919, ENST00000879920, ENST00000936140, ENST00000971852, ENST00000971853, ENST00000971854, ENST00000971855

RefSeq mRNA: 6 — MANE Select: NM_000857 NM_000857, NM_001291951, NM_001291952, NM_001291953, NM_001291954, NM_001291955

CCDS: CCDS47154, CCDS75203, CCDS77975, CCDS77976, CCDS77977, CCDS77978

Canonical transcript exons

ENST00000264424 — 14 exons

Exon	Start	End
ENSE00000385694	155789714	155789911
ENSE00000740142	155805103	155805229
ENSE00000740145	155804593	155804747
ENSE00000740150	155802342	155802579
ENSE00000740152	155799877	155800074
ENSE00000740154	155796377	155796510
ENSE00000740156	155795341	155795457
ENSE00000740158	155793856	155794086
ENSE00000856058	155803624	155803764
ENSE00001716583	155806386	155807811
ENSE00002034801	155759021	155759143
ENSE00003534048	155759787	155759860
ENSE00003624850	155777524	155777642
ENSE00003662474	155774968	155775068

Expression profiles

Bgee: expression breadth ubiquitous, 284 present calls, max score 98.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.4432 / max 574.1446, expressed in 1185 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
50215	14.0439	1175
50214	0.3300	125
50216	0.0694	41

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	98.32	gold quality
orbitofrontal cortex	UBERON:0004167	97.84	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.44	gold quality
superior frontal gyrus	UBERON:0002661	97.43	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.33	gold quality
postcentral gyrus	UBERON:0002581	96.97	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.90	gold quality
parietal lobe	UBERON:0001872	96.85	gold quality
substantia nigra pars compacta	UBERON:0001965	96.82	gold quality
pons	UBERON:0000988	96.75	gold quality
entorhinal cortex	UBERON:0002728	96.64	gold quality
superior vestibular nucleus	UBERON:0007227	96.36	gold quality
lateral globus pallidus	UBERON:0002476	96.10	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.67	gold quality
CA1 field of hippocampus	UBERON:0003881	95.52	gold quality
blood vessel layer	UBERON:0004797	95.51	gold quality
prefrontal cortex	UBERON:0000451	95.33	gold quality
heart right ventricle	UBERON:0002080	95.05	gold quality
ventral tegmental area	UBERON:0002691	94.87	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.86	gold quality
type B pancreatic cell	CL:0000169	94.85	gold quality
Brodmann (1909) area 10	UBERON:0013541	94.59	gold quality
urethra	UBERON:0000057	94.48	gold quality
frontal cortex	UBERON:0001870	94.36	gold quality
endothelial cell	CL:0000115	94.32	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.31	gold quality
nucleus accumbens	UBERON:0001882	94.17	gold quality
cerebral cortex	UBERON:0000956	93.77	gold quality
neocortex	UBERON:0001950	93.71	gold quality
visceral pleura	UBERON:0002401	93.65	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	38.11
E-HCAD-11	yes	21.51
E-MTAB-8410	yes	16.06
E-ANND-3	yes	13.12
E-MTAB-9067	yes	12.43

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GFI1, NFIC

miRNA regulators (miRDB)

113 targeting GUCY1B1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502

Literature-anchored findings (GeneRIF, showing 16)

• Although soluble guanylate cyclase(sGC) beta1-subunit expression was increased in mononuclear cells from patients with erectile dysfunction, the sGC activity was reduced (PMID:16528291)
• Results show that NOGCbeta1 and GC-A interact and that NOGCbeta1 regulates atrial natriuretic peptide signaling in HK-2 cells. (PMID:20024606)
• recombinant soluble guanylate cyclase (sGC) beta1 subunit and truncated N-terminal fragments expressed in E. coli; studied interaction between NO and sGC and schematic mechanism was proposed; study provides insights into structure and NO-binding of sGC (PMID:20063108)
• The mutant analysis indicated an importance for not only certain dimerization residue positions, but also an important role for other faces of the coiled coil dimer which might perhaps interact with adjacent domains (PMID:20105301)
• Data show that show that it is possible to directly monitor the sGC haem oxidation state in intact cells. By inserting the TC motif into the coding sequence of the beta1 subunit of sGC in transiently transfected Chinese hamster ovary cells. (PMID:21858179)
• We concluded that the alpha-subunit and the beta(1)(191-619) domain exert structural strains on the heme domain. (PMID:22223482)
• The results indicate that in comparison with the alpha-1 beta-1 isoform, the brain alpha-2 beta-1 isoform exhibits a distinctly different CO/NO affinity and binding rate in favor of NO signaling. (PMID:22426988)
• The G-protein regulator LGN modulates the activity of the NO receptor soluble guanylate cyclase (PMID:22690686)
• Gene expression in dendritic cells of CCL5 and CXCL5 as well as TIMP1 and GUCY1B3 showed a significant increase within the first 4 days after trauma. (PMID:23179318)
• Dynamic interplay between hsp90, apo-sGC-beta1, and sGC-alpha1 in response to NO is unprecedented and represent new steps by which cells can modulate the heme content and activity of sGC for signaling cascades. (PMID:24733395)
• The kinetics of heme loss from oxidized sGC was monitored by a new method based on the heme group de-quenching the fluorescence of FlAsH-EDT2. (PMID:26876536)
• Inhibition of HDAC3 with targeted therapy could benefit treatment of the diseases associated with sGCbeta1 down-regulation and/or deficiency such as cancer and several vascular-related diseases. (PMID:27279362)
• Human Red Blood Cells carry catalytically active alpha1beta1-soluble guanylate cyclase (isoform 1). Red cell soluble guanylate cyclase activity is fully preserved in patients with stable coronary artery disease. (PMID:29024896)
• Our observations revealed that rs7638A/C polymorphism of GUCY1B3 and the longer telomere length inclined toward adaptation to high altitude. (PMID:29443612)
• Results suggest mechanistic insights into the molecular pathway for soluble guanylyl cyclase (sGC) activation. (PMID:31645439)
• Inflammation in the Human Periodontium Induces Downregulation of the alpha1- and beta1-Subunits of the sGC in Cementoclasts. (PMID:33430449)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gucy1b1	ENSDARG00000086790
mus_musculus	Gucy1b1	ENSMUSG00000028005
rattus_norvegicus	Gucy1b1	ENSRNOG00000012060
drosophila_melanogaster	Gycbeta100B	FBGN0013973

Paralogs (17): GUCY2C (ENSG00000070019), ADCY2 (ENSG00000078295), GUCY2F (ENSG00000101890), NPR3 (ENSG00000113389), ADCY7 (ENSG00000121281), ADCY4 (ENSG00000129467), GUCY2D (ENSG00000132518), ADCY3 (ENSG00000138031), GUCY1A2 (ENSG00000152402), ADCY8 (ENSG00000155897), NPR2 (ENSG00000159899), ADCY9 (ENSG00000162104), GUCY1A1 (ENSG00000164116), ADCY1 (ENSG00000164742), NPR1 (ENSG00000169418), ADCY5 (ENSG00000173175), ADCY6 (ENSG00000174233)

Protein

Protein identifiers

Guanylate cyclase soluble subunit beta-1 — Q02153 (reviewed: Q02153)

Alternative names: Guanylate cyclase soluble subunit beta-3, Soluble guanylate cyclase small subunit

All UniProt accessions (5): Q02153, A0A494C1B9, B7Z685, D6RC99, E9PCN2

UniProt curated annotations — full annotation on UniProt →

Function. Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP.

Subunit / interactions. The active enzyme is formed by a heterodimer of an alpha and a beta subunit. Heterodimer with GUCY1A1. Can also form inactive homodimers in vitro.

Subcellular location. Cytoplasm.

Tissue specificity. Detected in brain cortex and cerebellum (at protein level).

Activity regulation. Activated by nitric oxide in the presence of magnesium or manganese ions.

Cofactor. Binds 1 or 2 heme groups per heterodimer. Heme is required for responding to nitric oxide, but not for catalytic activity.

Miscellaneous. There are two types of guanylate cyclases: soluble forms and membrane-associated receptor forms.

Similarity. Belongs to the adenylyl cyclase class-4/guanylyl cyclase family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q02153-1	HSGC-1	yes
Q02153-2	HSGC-2
Q02153-3	3

RefSeq proteins (6): NP_000848, NP_001278880, NP_001278881, NP_001278882, NP_001278883, NP_001278884 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001054	A/G_cyclase	Domain
IPR011644	Heme_NO-bd	Domain
IPR011645	HNOB_dom_associated	Domain
IPR018297	A/G_cyclase_CS	Conserved_site
IPR024096	NO_sig/Golgi_transp_ligand-bd	Homologous_superfamily
IPR029787	Nucleotide_cyclase	Homologous_superfamily
IPR038158	H-NOX_domain_sf	Homologous_superfamily
IPR042463	HNOB_dom_associated_sf	Homologous_superfamily

Pfam: PF00211, PF07700, PF07701

Enzyme classification (BRENDA):

• EC 4.6.1.2 — guanylate cyclase (BRENDA: 58 organisms, 213 substrates, 212 inhibitors, 100 Km, 16 kcat entries)

Substrate kinetics (BRENDA)

5 substrates with measured Km, best-characterized 5. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GTP	0.01–6.09	90
2’-O-(N-METHYLANTHRANILOYL) GUANOSINE 5’-TRIPHOS	0.0357	1
GUANYL-(BETA,GAMMA-METHYLENE)-DIPHOSPHONATE	0.37	1
GUANYL-IMIDODIPHOSPHATE	0.07	1
MN2+	2.7	1

Catalyzed reactions (Rhea), 1 shown:

• GTP = 3’,5’-cyclic GMP + diphosphate (RHEA:13665)

UniProt features (60 total): strand 25, helix 22, turn 8, splice variant 2, chain 1, domain 1, binding site 1

Structure

Experimental structures (PDB)

14 structures.

PDB	Method	Resolution (Å)
2WZ1	X-RAY DIFFRACTION	1.63
4NI2	X-RAY DIFFRACTION	1.9
3UVJ	X-RAY DIFFRACTION	2.08
8HBF	ELECTRON MICROSCOPY	3.1
8HBH	ELECTRON MICROSCOPY	3.1
8HBE	ELECTRON MICROSCOPY	3.2
7D9R	ELECTRON MICROSCOPY	3.7
6JT2	ELECTRON MICROSCOPY	3.8
7D9U	ELECTRON MICROSCOPY	3.8
6JT1	ELECTRON MICROSCOPY	3.9
7D9S	ELECTRON MICROSCOPY	3.9
6JT0	ELECTRON MICROSCOPY	4
7D9T	ELECTRON MICROSCOPY	4.1
5MNW	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q02153-F1	85.39	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 105 (proximal binding residue)

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-392154	Nitric oxide stimulates guanylate cyclase
R-HSA-445355	Smooth Muscle Contraction

MSigDB gene sets: 251 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, chr4q32, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_CGMP_BIOSYNTHETIC_PROCESS, GOZGIT_ESR1_TARGETS_DN, MODULE_445, MODULE_65, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_CYCLIC_NUCLEOTIDE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS

GO Biological Process (9): cGMP biosynthetic process (GO:0006182), obsolete nitric oxide mediated signal transduction (GO:0007263), blood circulation (GO:0008015), obsolete cGMP-mediated signaling (GO:0019934), nitric oxide-cGMP-mediated signaling (GO:0038060), response to oxygen levels (GO:0070482), cellular response to nitric oxide (GO:0071732), cyclic nucleotide biosynthetic process (GO:0009190), intracellular signal transduction (GO:0035556)

GO Molecular Function (14): adenylate cyclase activity (GO:0004016), guanylate cyclase activity (GO:0004383), GTP binding (GO:0005525), heme binding (GO:0020037), signaling receptor activity (GO:0038023), protein-containing complex binding (GO:0044877), metal ion binding (GO:0046872), cytidylate cyclase activity (GO:0047805), Hsp90 protein binding (GO:0051879), nitric oxide binding (GO:0070026), nucleotide binding (GO:0000166), protein binding (GO:0005515), lyase activity (GO:0016829), phosphorus-oxygen lyase activity (GO:0016849)

GO Cellular Component (6): cytosol (GO:0005829), guanylate cyclase complex, soluble (GO:0008074), presynaptic active zone cytoplasmic component (GO:0098831), glutamatergic synapse (GO:0098978), cytoplasm (GO:0005737), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Platelet homeostasis	1
Muscle contraction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cyclase activity	3
phosphorus-oxygen lyase activity	3
cyclic nucleotide biosynthetic process	2
intracellular anatomical structure	2
binding	2
cellular anatomical structure	2
purine ribonucleotide biosynthetic process	1
cGMP metabolic process	1
circulatory system process	1
intracellular signaling cassette	1
response to abiotic stimulus	1
response to nitric oxide	1
cellular response to oxygen-containing compound	1
cellular response to reactive nitrogen species	1
nucleotide biosynthetic process	1
cyclic nucleotide metabolic process	1
signal transduction	1
cGMP biosynthetic process	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
tetrapyrrole binding	1
molecular transducer activity	1
cation binding	1
heat shock protein binding	1
small molecule binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
catalytic activity	1
lyase activity	1
cytoplasm	1
cytosol	1
catalytic complex	1
presynaptic active zone	1
cell cortex region	1
synapse	1
cellular_component	1

Protein interactions and networks

STRING

1138 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GUCY1B1	GUCY1A1	Q02108	950
GUCY1B1	GUCY1A2	P33402	834
GUCY1B1	PDE5A	O76074	561
GUCY1B1	AK8	Q96MA6	488
GUCY1B1	PDE7B	Q9NP56	486
GUCY1B1	PRKG2	Q13237	451
GUCY1B1	NTPCR	Q9BSD7	451
GUCY1B1	PRKG1	P14619	444
GUCY1B1	LY6G6F	Q5SQ64	441
GUCY1B1	DLG4	P78352	424
GUCY1B1	CTSO	P43234	407
GUCY1B1	ATIC	P31939	403
GUCY1B1	CANT1	Q8WVQ1	395
GUCY1B1	IRAG1	Q9Y6F6	390
GUCY1B1	GFI1B	Q5VTD9	385

IntAct

25 interactions, top by confidence:

A	B	Type	Score
LIN7A	CASK	psi-mi:“MI:0914”(association)	0.830
GUCY1A1	GUCY1B1	psi-mi:“MI:0407”(direct interaction)	0.670
GUCY1A1	GUCY1B1	psi-mi:“MI:0883”(gtpase reaction)	0.670
GUCY1B1	GUCY1B1	psi-mi:“MI:0407”(direct interaction)	0.440
IMMP2L	ANKHD1-EIF4EBP3	psi-mi:“MI:0914”(association)	0.350
	ABCD4	psi-mi:“MI:0914”(association)	0.350
OR1M1	NBAS	psi-mi:“MI:0914”(association)	0.350
ZDHHC12	NBAS	psi-mi:“MI:0914”(association)	0.350
PRKY	METTL15	psi-mi:“MI:0914”(association)	0.350
OR6T1	PSMD11	psi-mi:“MI:0914”(association)	0.350
HNRNPCL2	SMCHD1	psi-mi:“MI:0914”(association)	0.350
TLR9	ABCD4	psi-mi:“MI:0914”(association)	0.350
ABCA2	ABCD4	psi-mi:“MI:0914”(association)	0.350
GRIN3B	DAPK3	psi-mi:“MI:0914”(association)	0.350
ANKMY2	ADCY6	psi-mi:“MI:0914”(association)	0.350
OR2M7	MARCHF6	psi-mi:“MI:0914”(association)	0.350
SLC12A3	SNX2	psi-mi:“MI:0914”(association)	0.350
GUCY1B1	MYCBP2	psi-mi:“MI:0914”(association)	0.350
USP28	OFD1	psi-mi:“MI:0914”(association)	0.350
NOX5	RNASEH2A	psi-mi:“MI:0914”(association)	0.350
CHRNA7	UFL1	psi-mi:“MI:0914”(association)	0.350
GUCY1B1	MXRA7	psi-mi:“MI:0914”(association)	0.350
SLC27A6	NBAS	psi-mi:“MI:0914”(association)	0.350
DSCR9	GUCY1B1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (56): GUCY1B3 (Affinity Capture-MS), GUCY1A2 (Affinity Capture-MS), GUCY1A3 (Affinity Capture-MS), MXRA7 (Affinity Capture-MS), GUCY1B3 (Affinity Capture-MS), UACA (Affinity Capture-MS), GUCY1B3 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS), MYCBP2 (Affinity Capture-MS), BBS2 (Affinity Capture-MS), MUL1 (Affinity Capture-MS), GUCY1B3 (Affinity Capture-RNA), NOS3 (Reconstituted Complex), HSP90AA1 (Reconstituted Complex), NOS3 (Affinity Capture-Western)

ESM2 similar proteins: A0A2R8QFQ6, A0A2R8RWN9, D3Z7P3, E9PV86, G3MWR8, O54865, O60907, O89050, O94925, P13264, P16068, P20595, P58058, Q02153, Q08211, Q12800, Q13042, Q14722, Q28141, Q28D01, Q3MHJ2, Q3ULA2, Q4R8H1, Q4ZHR9, Q5R874, Q5RB35, Q5SP67, Q5SRY7, Q5ZHN3, Q6DN14, Q7RTP6, Q7T2U9, Q7Z6J6, Q8BTG7, Q8C6G8, Q8CJ19, Q8K4Q0, Q8N122, Q8N2K0, Q8R349

Diamond homologs: A0A078BQP2, A0A0U1RPR8, E7EAU8, H2L002, O02298, O02740, O16715, O19179, O54865, O62179, O75343, P0A4Y1, P16065, P16066, P16068, P18293, P18910, P19686, P19687, P20594, P20595, P22717, P23897, P25092, P26770, P33402, P51840, P51841, P51842, P52785, P55202, P55203, P55204, P70106, P90895, P91550, P92006, P9WQ34, P9WQ35, Q02108

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
GUCY1B1	“form complex”	GUCY1A2-B3	binding
GUCY1B1	“form complex”	GUCY1A3-B3	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2338 predictions. Top by Δscore:

Variant	Effect	Δscore
4:155759782:CGCAG:C	acceptor_loss	1.0000
4:155759785:A:AG	acceptor_gain	1.0000
4:155759785:AGTAC:A	acceptor_gain	1.0000
4:155759786:G:GA	acceptor_gain	1.0000
4:155759786:GT:G	acceptor_gain	1.0000
4:155759786:GTAC:G	acceptor_gain	1.0000
4:155759786:GTACG:G	acceptor_gain	1.0000
4:155759861:G:GG	donor_gain	1.0000
4:155774952:T:TA	acceptor_gain	1.0000
4:155774958:T:TA	acceptor_gain	1.0000
4:155774964:CCAG:C	acceptor_loss	1.0000
4:155774966:A:AG	acceptor_gain	1.0000
4:155774966:AG:A	acceptor_loss	1.0000
4:155774967:G:GA	acceptor_gain	1.0000
4:155774967:GA:G	acceptor_gain	1.0000
4:155774967:GAA:G	acceptor_gain	1.0000
4:155774967:GAAA:G	acceptor_gain	1.0000
4:155774967:GAAAA:G	acceptor_gain	1.0000
4:155775064:CCTCA:C	donor_gain	1.0000
4:155775065:CTCAG:C	donor_loss	1.0000
4:155775066:TCA:T	donor_gain	1.0000
4:155775067:CA:C	donor_gain	1.0000
4:155775067:CAGT:C	donor_loss	1.0000
4:155775068:AGTA:A	donor_loss	1.0000
4:155775069:G:GG	donor_gain	1.0000
4:155775070:TAAG:T	donor_loss	1.0000
4:155775071:AAGTT:A	donor_loss	1.0000
4:155777508:T:A	acceptor_gain	1.0000
4:155777511:A:AG	acceptor_gain	1.0000
4:155777517:A:AG	acceptor_gain	1.0000

AlphaMissense

4101 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:155759790:G:A	G3R	1.000
4:155759790:G:C	G3R	1.000
4:155759791:G:A	G3E	1.000
4:155775053:G:C	A55P	1.000
4:155777556:G:A	G71R	1.000
4:155777556:G:C	G71R	1.000
4:155777556:G:T	G71W	1.000
4:155777557:G:A	G71E	1.000
4:155777557:G:T	G71V	1.000
4:155777578:G:A	C78Y	1.000
4:155777579:C:G	C78W	1.000
4:155777605:T:C	L87S	1.000
4:155777614:T:C	L90P	1.000
4:155777616:G:C	G91R	1.000
4:155777616:G:T	G91C	1.000
4:155777617:G:A	G91D	1.000
4:155777617:G:T	G91V	1.000
4:155777634:T:C	F97L	1.000
4:155777635:T:C	F97S	1.000
4:155777636:T:A	F97L	1.000
4:155777636:T:G	F97L	1.000
4:155777638:T:C	L98P	1.000
4:155789718:T:A	L101H	1.000
4:155789718:T:C	L101P	1.000
4:155789720:G:C	D102H	1.000
4:155789720:G:T	D102Y	1.000
4:155789721:A:C	D102A	1.000
4:155789721:A:T	D102V	1.000
4:155789727:T:C	L104P	1.000
4:155789729:C:G	H105D	1.000

dbSNP variants (sampled 300 via entrez): RS1000028198 (4:155767712 C>T), RS1000181745 (4:155789242 A>C), RS1000214956 (4:155795901 A>G), RS1000241336 (4:155788301 A>G), RS10003470 (4:155788060 A>G), RS1000401243 (4:155780938 A>C,G), RS1000495696 (4:155771386 T>C,G), RS1000728651 (4:155804542 A>G,T), RS1000739942 (4:155804345 C>T), RS1000784620 (4:155778053 A>G), RS1000801418 (4:155786931 A>G), RS1000842573 (4:155788732 G>A), RS1000873490 (4:155760869 C>G), RS1000886782 (4:155757800 T>C), RS1000913272 (4:155807557 T>C)

Disease associations

OMIM: gene MIM:139397 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001227_20	Systolic blood pressure	1.000000e-06
GCST001228_9	Diastolic blood pressure	2.000000e-10
GCST001236_17	Blood pressure	3.000000e-07
GCST004278_64	Pulse pressure	7.000000e-14
GCST004776_19	Systolic blood pressure	5.000000e-06
GCST004777_5	Diastolic blood pressure	2.000000e-06
GCST006259_49	Systolic blood pressure	7.000000e-09
GCST007707_36	Hypertension	6.000000e-06
GCST009840_2	Diabetic retinopathy in type 2 diabetes	4.000000e-06
GCST010867_31	Coronary artery disease	3.000000e-08

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0006336	diastolic blood pressure
EFO:0006340	mean arterial pressure
EFO:0005763	pulse pressure measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2111348 (PROTEIN COMPLEX GROUP), CHEMBL3137281 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 8,203 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL12610	BENZYDAMINE	4	8,193
CHEMBL5944803	FRESPACIGUAT	2	10

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase

Binding affinities (BindingDB)

465 measured of 465 human assays (465 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
4-amino-2-[6-chloro-1-[(2-fluorophenyl)methyl]indazol-3-yl]-5-methyl-5-[3-(2H-tetrazol-5-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-one	KI	0.068 nM	US-10428076: Soluble guanylate cyclase stimulators
3-[2-[4-[(5S)-2-[6-chloro-1-[(2-fluorophenyl)methyl]indazol-3-yl]-5-methyl-6-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl]ethyl]-1,2,4-oxadiazolidin-5-one	KI	0.074 nM	US-10428076: Soluble guanylate cyclase stimulators
(1R,6S)-3-[6-[2-[[2-[[(2S)-1,4-dioxan-2-yl]methyl]-5-methyl-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	1 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[2-(1,4-dioxan-2-ylmethyl)-5,8-dimethyl-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	1 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-3-methoxy-1-[6-[3-methyl-2-[[6-methyl-3-(oxan-4-yl)-1,2,4,5-tetrahydro-3-benzazepin-8-yl]methoxy]phenyl]-2-pyridinyl]piperidine-4-carboxylic acid	EC50	1 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-3-methoxy-1-[6-[3-methyl-2-[[6-methyl-3-[(3S)-oxolan-3-yl]-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]phenyl]-2-pyridinyl]piperidine-4-carboxylic acid	EC50	1 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3R,4R)-1-[4-[3-chloro-2-[[(5R)-5-methyl-3-(oxan-4-yl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-methoxypiperidine-4-carboxylic acid	EC50	1 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-1-[6-[2-[[5,5-dimethyl-3-(oxetan-3-yl)-2,4-dihydro-1H-3-benzazepin-7-yl]methoxy]-3-methylphenyl]-2-pyridinyl]-3-methoxypiperidine-4-carboxylic acid	EC50	1 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[6-[3-methyl-2-[[8-methyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[6-[5-methyl-2-[[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,5R)-3-[6-[3-methyl-2-[[6-methyl-3-(oxetan-3-yl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hexane-1-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[2-(1,4-dioxan-2-ylmethyl)-5-methyl-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[3-methyl-2-[[5-methyl-2-(oxan-3-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[3-methyl-2-[[8-methyl-2-(oxolan-3-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[3-methyl-2-[[8-methyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[3-methyl-2-[[8-methyl-2-(oxetan-3-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[3-methyl-2-[[6-methyl-3-(oxan-4-yl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[2-(1,4-dioxan-2-ylmethyl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-5-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[2-(1,4-dioxan-2-ylmethyl)-5-methyl-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-5-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-3-ethoxy-1-[4-[2-[[5-fluoro-8-methyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]piperidine-4-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3R,4R)-1-[4-[2-[[5-fluoro-8-methoxy-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-methoxypiperidine-4-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-3-ethoxy-1-[4-[2-[[5-fluoro-8-methoxy-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]piperidine-4-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-3-ethoxy-1-[4-[2-[[5-fluoro-8-methoxy-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-5-methylphenyl]-1,3-thiazol-2-yl]piperidine-4-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-3-methoxy-1-[6-[3-methyl-2-[[6-methyl-3-(oxetan-3-yl)-1,2,4,5-tetrahydro-3-benzazepin-8-yl]methoxy]phenyl]-2-pyridinyl]piperidine-4-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[2-(4,4-difluorocyclohexyl)-8-methyl-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3R,4R)-1-[4-[2-[[5,5-dimethyl-3-(oxan-4-yl)-2,4-dihydro-1H-3-benzazepin-7-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-methoxypiperidine-4-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-1-[6-[2-[[5,5-dimethyl-3-(oxan-4-yl)-2,4-dihydro-1H-3-benzazepin-7-yl]methoxy]-3-methylphenyl]-2-pyridinyl]-3-methoxypiperidine-4-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-1-[4-[5-fluoro-3-methyl-2-[[(5R)-5-methyl-3-(oxan-4-yl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-methoxypiperidine-4-carboxylic acid	EC50	2 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[6-[2-[[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[6-[2-[[2-(1,4-dioxan-2-ylmethyl)-5-methyl-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[6-[3-methyl-2-[[5-methyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[2-(1,4-dioxan-2-ylmethyl)-8-methyl-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[3-methyl-2-[[8-methyl-2-(oxan-3-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[5,8-dimethyl-2-(oxan-3-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[5,8-dimethyl-2-(oxolan-3-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[5,8-dimethyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[5,8-dimethyl-2-(oxetan-3-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-3-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[5-methyl-2-[[5-methyl-2-(oxolan-3-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[4-[2-[[2-(1,4-dioxan-2-ylmethyl)-5,8-dimethyl-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]-5-methylphenyl]-1,3-thiazol-2-yl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-3-methoxy-1-[6-[3-methyl-2-[[6-methyl-3-(oxetan-3-yl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]phenyl]-2-pyridinyl]piperidine-4-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,2S,5R)-3-[6-[2-[[6-fluoro-3-(oxan-4-yl)-1,2,4,5-tetrahydro-3-benzazepin-8-yl]methoxy]-3-methylphenyl]-2-pyridinyl]-2-(methoxymethyl)-3-azabicyclo[3.1.0]hexane-1-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3R,4R)-1-[6-[3-chloro-2-[[8-methyl-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-ethoxypiperidine-4-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3R,4R)-1-[6-[3-chloro-2-[[8-methoxy-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-ethoxypiperidine-4-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3R,4R)-1-[4-[3-chloro-2-[[8-methoxy-2-(oxan-4-yl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-1,3-thiazol-2-yl]-3-ethoxypiperidine-4-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,2S,5R)-3-[6-[2-[[6-fluoro-3-(oxan-4-yl)-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]-3-methylphenyl]-2-pyridinyl]-2-(methoxymethyl)-3-azabicyclo[3.1.0]hexane-1-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[6-[2-[(2-cyclobutyl-5-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(3S,4S)-3-methoxy-1-[6-[3-methyl-2-[[6-methyl-3-[(3R)-oxolan-3-yl]-1,2,4,5-tetrahydro-3-benzazepin-7-yl]methoxy]phenyl]-2-pyridinyl]piperidine-4-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[6-[2-[[5-methyl-2-(1-pyridin-2-ylethyl)-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
(1R,6S)-3-[6-[2-[[5-methyl-2-[(5-methyl-1,2-oxazol-3-yl)methyl]-3,4-dihydro-1H-isoquinolin-6-yl]methoxy]phenyl]-2-pyridinyl]-3-azabicyclo[4.1.0]heptane-6-carboxylic acid	EC50	3 nM	US-9353090: Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

ChEMBL bioactivities

909 potent at pChembl≥5 of 962 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.66	Ki	0.022	nM	CHEMBL5814188
10.59	Ki	0.026	nM	CHEMBL5961042
10.54	Ki	0.029	nM	CHEMBL5937094
10.51	Ki	0.031	nM	CHEMBL5962881
10.51	Ki	0.031	nM	CHEMBL5896066
10.51	Ki	0.031	nM	CHEMBL5828124
10.41	Ki	0.039	nM	CHEMBL5754765
10.39	Ki	0.041	nM	CHEMBL6025572
10.38	Ki	0.042	nM	CHEMBL5943807
10.35	Ki	0.045	nM	CHEMBL5924970
10.33	Ki	0.047	nM	CHEMBL5980517
10.32	Ki	0.048	nM	CHEMBL5989618
10.31	Ki	0.049	nM	CHEMBL6038148
10.30	Ki	0.05	nM	CHEMBL5915567
10.28	Ki	0.052	nM	CHEMBL6021981
10.28	Ki	0.052	nM	CHEMBL6053909
10.25	Ki	0.056	nM	CHEMBL5838947
10.24	Ki	0.058	nM	CHEMBL5925728
10.24	Ki	0.057	nM	CHEMBL6031103
10.24	Ki	0.058	nM	CHEMBL6006393
10.24	Ki	0.057	nM	CHEMBL5959396
10.24	Ki	0.058	nM	CHEMBL5981554
10.22	Ki	0.06	nM	CHEMBL5872155
10.21	Ki	0.062	nM	CHEMBL6055856
10.21	Ki	0.062	nM	CHEMBL6011397
10.21	Ki	0.062	nM	CHEMBL5946879
10.20	Ki	0.063	nM	CHEMBL5973404
10.20	Ki	0.063	nM	CHEMBL6050464
10.19	Ki	0.064	nM	CHEMBL5941930
10.18	Ki	0.066	nM	CHEMBL5850021
10.18	Ki	0.066	nM	CHEMBL5754222
10.17	Ki	0.067	nM	CHEMBL5758630
10.17	Ki	0.067	nM	CHEMBL5842014
10.17	Ki	0.067	nM	CHEMBL6019970
10.17	Ki	0.068	nM	CHEMBL5996734
10.17	Ki	0.068	nM	CHEMBL5870392
10.15	Ki	0.07	nM	CHEMBL5979143
10.15	Ki	0.07	nM	CHEMBL5977775
10.14	Ki	0.072	nM	CHEMBL6065117
10.14	Ki	0.073	nM	CHEMBL6023523
10.13	Ki	0.074	nM	CHEMBL6064339
10.13	Ki	0.074	nM	CHEMBL5908747
10.13	Ki	0.074	nM	CHEMBL5862357
10.12	Ki	0.075	nM	CHEMBL5855606
10.12	Ki	0.075	nM	CHEMBL5981113
10.12	Ki	0.075	nM	CHEMBL5793164
10.12	Ki	0.076	nM	CHEMBL5965599
10.11	Ki	0.078	nM	CHEMBL5828379
10.11	Ki	0.077	nM	CHEMBL6032838
10.10	Ki	0.079	nM	CHEMBL5972747

PubChem BioAssay actives

72 with measured affinity, of 284 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]piperidine-4-carboxylic acid	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0070	uM
1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]piperidin-4-ol	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0100	uM
5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-N-methylpyrimidin-4-amine	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0200	uM
3-[1-[(2-fluorophenyl)methyl]-3-(5-fluoro-4-piperidin-1-ylpyrimidin-2-yl)pyrazol-5-yl]-1,2-oxazole	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0270	uM
1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]piperidin-3-ol	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0330	uM
(2R,3S)-1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]-3-methylpiperidine-2-carboxylic acid	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0330	uM
[1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]piperidin-2-yl]methanol	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0350	uM
(2S,3R)-1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]-3-methylpiperidine-2-carboxylic acid	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0400	uM
5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-N-(2-morpholin-4-ylethyl)pyrimidin-4-amine	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0410	uM
4-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]morpholine	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0500	uM
1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]piperidine-3-carboxylic acid	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0550	uM
3-[1-[(2-fluorophenyl)methyl]-3-(5-fluoro-4-pyrrolidin-1-ylpyrimidin-2-yl)pyrazol-5-yl]-1,2-oxazole	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0830	uM
5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1H-pyrimidin-6-one	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.0970	uM
methyl N-[4,6-diamino-2-[3-[(2,3,5-trifluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methylcarbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.1100	uM
6-amino-2-[3-[(2-fluorophenyl)methyl]indazol-1-yl]-7-methyl-9H-purin-8-one	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.1200	uM
3-[1-[(2-fluorophenyl)methyl]-3-(5-fluoro-4-piperazin-1-ylpyrimidin-2-yl)pyrazol-5-yl]-1,2-oxazole	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.1200	uM
(2R)-1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]piperidine-2-carboxylic acid	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.1200	uM
5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-amine	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.1300	uM
6-amino-2-[5-chloro-3-[(2-fluorophenyl)methyl]indazol-1-yl]-7-methyl-9H-purin-8-one	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.1400	uM
3-[3-[4-(3,3-difluoropiperidin-1-yl)-5-fluoropyrimidin-2-yl]-1-[(2-fluorophenyl)methyl]pyrazol-5-yl]-1,2-oxazole	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.1500	uM
4-amino-2-[3-[(2-fluorophenyl)methyl]indazol-1-yl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.1600	uM
5-(4-chlorophenyl)sulfonyl-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.1600	uM
5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-thiazol-3-yl)pyrazol-3-yl]-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.1800	uM
6-amino-7-ethyl-2-[3-[(2-fluorophenyl)methyl]indazol-1-yl]-9H-purin-8-one	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.2000	uM
(2S)-1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]piperidine-2-carboxylic acid	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.2000	uM
2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-amine	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.2400	uM
5-fluoro-2-[1-[(2-fluoro-3-methylphenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.2400	uM
4-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]-1,4-thiazinane 1,1-dioxide	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.2400	uM
3-[3-[4-(4,4-difluoropiperidin-1-yl)-5-fluoropyrimidin-2-yl]-1-[(2-fluorophenyl)methyl]pyrazol-5-yl]-1,2-oxazole	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.2500	uM
methyl N-[4,6-diamino-2-[3-[(2,5-difluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methylcarbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.2700	uM
methyl N-[4,6-diamino-2-[3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methylcarbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.2700	uM
5-fluoro-2-[1-[(3-fluorothiophen-2-yl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.2800	uM
methyl N-[4,6-diamino-2-[3-[(2,3-difluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methylcarbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.3000	uM
6-amino-2-[3-[(2-fluorophenyl)methyl]indazol-1-yl]-7,9-dihydropurin-8-one	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.3000	uM
methyl N-[4,6-diamino-2-[3-[(2-fluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methylcarbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.3100	uM
3-[3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-[(2-fluorophenyl)methyl]pyrazol-5-yl]-1,2-oxazole	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.3200	uM
methyl N-[4,6-diamino-2-[5-chloro-3-[(2-fluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methylcarbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.3500	uM
5-(benzenesulfonyl)-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.3500	uM
2-[1-[(2,3-difluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-5-fluoro-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.3700	uM
2-[1-[(3-chloro-2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-5-fluoro-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.3800	uM
2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-6-oxo-1H-pyrimidine-5-carbonitrile	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.5000	uM
2-[1-[(2,4-difluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-5-fluoro-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.5300	uM
5-chloro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.5900	uM
methyl N-[4,6-diamino-2-[5-chloro-3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]carbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.6700	uM
methyl N-[4,6-diamino-2-[5-chloro-3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methylcarbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.7000	uM
2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-N-methyl-6-oxo-N-phenyl-1H-pyrimidine-5-sulfonamide	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.7300	uM
2-[1-benzyl-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-5-fluoro-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.8800	uM
2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-5-methylsulfonyl-1H-pyrimidin-6-one	1304082: Activation of SGC in HEK293 cells assessed as cGMP production after 20 mins by LC-MS/MS analysis in presence of NO-donor DETA-NONOate	ec50	0.9000	uM
methyl N-[4,6-diamino-2-[5-fluoro-3-[(2-fluorophenyl)methyl]indazol-1-yl]pyrimidin-5-yl]-N-methylcarbamate	1677320: Activation of human sGC subunit alpha1/beta1 expressed in CHO cells assessed as cGMP production by CASA assay	ec50	0.9600	uM
(2S)-1-[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]pyrrolidine-2-carboxylic acid	1757088: Activation of sGC (unknown origin) in presence of DETA-NO by Glosensor cGMP assay	ec50	0.9700	uM

CTD chemical–gene interactions

65 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	7
bisphenol A	decreases expression, increases expression	3
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one	increases activity, increases reaction, affects cotreatment, affects binding, affects folding (+1 more)	2
entinostat	affects cotreatment, decreases expression	2
ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate	affects cotreatment, affects expression	1
fluorene-9-bisphenol	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
trichostatin A	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	affects expression, affects cotreatment	1
protoporphyrin IX	increases activity, increases reaction, affects binding	1
potassium ferricyanide	affects binding, decreases reaction, increases activity	1
hydroquinone	increases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
pentanal	increases expression	1
perfluorooctane sulfonic acid	affects expression, affects cotreatment	1
1,1-diethyl-2-hydroxy-2-nitrosohydrazine	affects binding, increases activity, decreases reaction	1
3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole	affects binding, affects folding	1
CGP 52608	affects binding, increases reaction	1
3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine	affects binding, increases activity, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
BAY 58-2667	affects binding, affects cotreatment, increases activity, increases reaction	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dicyanocobinamide	affects binding, increases activity, increases reaction, decreases reaction, increases metabolic processing	1
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide	affects binding, increases activity, increases reaction	1
dorsomorphin	affects cotreatment, decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1

ChEMBL screening assays

45 unique, capped per target: 40 binding, 5 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1918701	Binding	Activation of human soluble guanylate cyclase assessed as production of cGMP in presence of nitric oxide donor, SIN-1 by LC-MS enzyme assay	Acidic triazoles as soluble guanylate cyclase stimulators. — Bioorg Med Chem Lett
CHEMBL865676	Functional	Effect on cGMP production in porcine iris-ciliary body at 10 uM	Synthesis and ocular effects of imidazole nitrolic acid and amidoxime esters. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.